Bay­er buys li­cense to Cedil­la pre­clin­i­cal can­cer pro­gram; MEI Phar­ma says no to un­so­licit­ed of­fer

Bay­er has ac­quired ex­clu­sive rights to Cedil­la Ther­a­peu­tics’ pre­clin­i­cal can­cer drug can­di­dates for an undis­closed amount.

Bay­er an­nounced Thurs­day morn­ing that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA